Fluid Management in Transient Tachypnea of the Newborn
A Randomized Controlled Trial of Fluid Management in Transient Tachypnea of the Newborn
1 other identifier
interventional
64
1 country
1
Brief Summary
Transient tachypnea of the newborn (TTN) is a diagnosis given to infants born between 34 and 42 weeks gestation who develop difficulty breathing during the first days of life when no specific cause of the breathing difficulty can be identified. Little is known about why some babies develop TTN, and there have not been many formal studies of the best way to take care of babies with this disease. Babies with TTN get better on their own within three to five days after birth, but may require extra oxygen to breath well. Most physicians believe that the symptoms of TTN are related to poor clearance of fluid from the newborn's lungs. Babies with TTN have extra fluid visible on chest x-ray. Diuretics, medicines that can help clear extra lung fluid in adults and in babies with extra lung fluid for other reasons, do not to help babies with TTN. Babies with TTN need intravenous fluids to be healthy because they breathe too fast to be able to eat. Breastfed babies only get a very small amount of fluid in the first few days of life, as it normally takes several days for a new mother to begin producing breastmilk. No one has yet examined whether giving babies with TTN an amount of fluid similar to the small amount they would receive if they could breastfeed would help them recover from TTN faster. In this study, the investigators compare whether giving newborns "standard" intravenous fluid or amounts of intravenous fluid more close to what a breastfed baby would receive speeds recovery in newborns with TTN.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for not_applicable
Started Jun 2008
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
June 1, 2008
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
September 1, 2010
CompletedFirst Submitted
Initial submission to the registry
October 18, 2010
CompletedFirst Posted
Study publicly available on registry
October 20, 2010
CompletedResults Posted
Study results publicly available
November 28, 2013
CompletedNovember 28, 2013
September 1, 2013
2.3 years
October 18, 2010
September 24, 2013
September 24, 2013
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Duration of Respiratory Support
every hour until patient stable without respiratory support, an average of approximately 55 hours and a maximum of 205 hours
Secondary Outcomes (2)
Duration of ICU Admission
every day until discharge, an average of approximately 8 days and a maximum of 12 days
Time to First Enteral Feed
hour until first enteral feed achieved, an average of approximately 40 hours and a maximum of 100 hours
Study Arms (2)
Standard Fluids
NO INTERVENTIONTerm neonates receive total fluids of 60 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
Restricted Fluids
EXPERIMENTALTerm neonates receive total fluids of 40 mL/kg/day on day of life (DOL) 1. Preterm neonates receive total fluids of 60 mL/kg/day on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved
Interventions
Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
Eligibility Criteria
You may qualify if:
- Gestational age at birth 34 and 42 weeks of gestation
- Admission to the Mount Sinai NICU during the first 24 hours of life
- Diagnosis during the first 24 hours of life of transient tachypnea of the newborn
You may not qualify if:
- Gestational age at birth less than 34 weeks or greater than 42 weeks at birth
- No diagnosis of TTN made in the first 24 hours of life
- Additional infant diagnosis of major cardiac disease
- Additional infant diagnosis of major pulmonary disease other than TTN
- Additional infant diagnosis of meconium aspiration syndrome
- Additional infant diagnosis of major congenital anomaly with potential to affect respiratory status in the neonatal period
- Additional infant diagnosis of infectious disease process potentially affecting respiratory status in the neonatal period
- Observation of thick meconium in the amniotic fluid at delivery.
- Maternal diagnosis of chorioamnionitis or other infection of the uterus or fallopian tubes pre- or peri-partum.
- Criteria for removal from the study:
- (a) Additional infant diagnosis of major cardiac, pulmonary, or other disease process potentially affecting respiratory status in the neonatal period (i.e., infection, meconium aspiration, pneumothorax, congenital anomaly) present during the study period. (b) Positive test of infection (e.g. blood, CSF, or urine culture; viral DFA; microscopy) drawn from infant at any point during the study period. (c) Maternal diagnosis of chorioamnionitis or other infection of the uterus or fallopian tubes at any point during hospital stay. (d) Objective clinical signs of dehydration: (i) Newborn urine output less than 2 mL/kg/hr over a twelve hour period at any point during the study period. (ii) Newborn serum sodium less than 130 mEq/L or greater than 150 mEq/L at any point during the study period. (iii) Newborn weight loss \>10% of birth weight at any point during the study period.
- (e) Newborn blood glucose by point-of-care testing of less than 40 mg/dL at any point during the study period. (f) Administration of exogenous surfactant at any point during the study period.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Mount Sinai School of Medicine
New York, New York, 10029, United States
Related Publications (12)
Avery ME, Gatewood OB, Brumley G. Transient tachypnea of newborn. Possible delayed resorption of fluid at birth. Am J Dis Child. 1966 Apr;111(4):380-5. doi: 10.1001/archpedi.1966.02090070078010. No abstract available.
PMID: 5906048BACKGROUNDZanardo V, Simbi AK, Franzoi M, Solda G, Salvadori A, Trevisanuto D. Neonatal respiratory morbidity risk and mode of delivery at term: influence of timing of elective caesarean delivery. Acta Paediatr. 2004 May;93(5):643-7. doi: 10.1111/j.1651-2227.2004.tb02990.x.
PMID: 15174788BACKGROUNDRiskin A, Abend-Weinger M, Riskin-Mashiah S, Kugelman A, Bader D. Cesarean section, gestational age, and transient tachypnea of the newborn: timing is the key. Am J Perinatol. 2005 Oct;22(7):377-82. doi: 10.1055/s-2005-872594.
PMID: 16215925BACKGROUNDJain L, Eaton DC. Physiology of fetal lung fluid clearance and the effect of labor. Semin Perinatol. 2006 Feb;30(1):34-43. doi: 10.1053/j.semperi.2006.01.006.
PMID: 16549212BACKGROUNDJain L, Dudell GG. Respiratory transition in infants delivered by cesarean section. Semin Perinatol. 2006 Oct;30(5):296-304. doi: 10.1053/j.semperi.2006.07.011.
PMID: 17011402BACKGROUNDDemissie K, Marcella SW, Breckenridge MB, Rhoads GG. Maternal asthma and transient tachypnea of the newborn. Pediatrics. 1998 Jul;102(1 Pt 1):84-90. doi: 10.1542/peds.102.1.84.
PMID: 9651418BACKGROUNDPersson B, Hanson U. Neonatal morbidities in gestational diabetes mellitus. Diabetes Care. 1998 Aug;21 Suppl 2:B79-84.
PMID: 9704232BACKGROUNDTutdibi E, Hospes B, Landmann E, Gortner L, Satar M, Yurdakok M, Dellagrammaticas H, Ors R, Ilikkan B, Ovali F, Sarman G, Kumral A, Arslanoglu S, Koc H, Yildiran A. Transient tachypnea of the newborn (TTN): a role for polymorphisms of surfactant protein B (SP-B) encoding gene? Klin Padiatr. 2003 Sep-Oct;215(5):248-52. doi: 10.1055/s-2003-42670.
PMID: 14520584BACKGROUNDAdams JM, Moreno J, Reynolds K, Campbell DW IV, Smith EO, Weisman LE. Resource utilization among neonatologists in a university children's hospital. Pediatrics. 1997 Jun;99(6):E2. doi: 10.1542/peds.99.6.e2.
PMID: 9164798BACKGROUNDLewis V, Whitelaw A. Furosemide for transient tachypnea of the newborn. Cochrane Database Syst Rev. 2002;(1):CD003064. doi: 10.1002/14651858.CD003064.
PMID: 11869651BACKGROUNDNeville MC, Morton J. Physiology and endocrine changes underlying human lactogenesis II. J Nutr. 2001 Nov;131(11):3005S-8S. doi: 10.1093/jn/131.11.3005S.
PMID: 11694636BACKGROUNDStroustrup A, Trasande L, Holzman IR. Randomized controlled trial of restrictive fluid management in transient tachypnea of the newborn. J Pediatr. 2012 Jan;160(1):38-43.e1. doi: 10.1016/j.jpeds.2011.06.027. Epub 2011 Aug 11.
PMID: 21839467DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
As a small, single center study, our results may not be fully generalizable to the TTN patient population in all hospital types on a national level.
Results Point of Contact
- Title
- Dr. Annemarie Stroustrup
- Organization
- Icahn School of Medicine at Mount Sinai
Study Officials
- PRINCIPAL INVESTIGATOR
Annemarie Stroustrup, MD, MPH
Icahn School of Medicine at Mount Sinai
Publication Agreements
- PI is Sponsor Employee
- Yes
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 18, 2010
First Posted
October 20, 2010
Study Start
June 1, 2008
Primary Completion
September 1, 2010
Study Completion
September 1, 2010
Last Updated
November 28, 2013
Results First Posted
November 28, 2013
Record last verified: 2013-09